Popular Antibiotics May Have Catastrophic Side Effects - Bisnar Chase Law Firm Weighs In

Share Article

Orange County defective drug lawyer weighs in on the dangers faced by unsuspecting consumers who take antibiotics for infections without realizing some of the devastating side effects they may experience. A popular class of antibiotics called fluoroquinolones has been the subject of thousands of lawsuits filed by patients who have suffered severe reactions after taking them.

leaquin antibiotic

Levaquin and other antibiotics may pose risk

While it is common for most medications – over the counter or prescription – to have some type of side effect, such serious life threatening reactions are unacceptable.

The Orange County pharmaceutical litigation attorneys at Bisnar Chase have represented hundreds of consumers over the last 30 years who have suffered severe side effects as a result of medications. According to a Sept. 10 report in The New York Times, fluoroquinolones such as Levaquin, which was the best-selling antibiotic in the United States in 2010, was the subject of more than 2,000 lawsuits where those who took the drug complained of side effects ranging from tendonitis and tendon rupture to vision problems and kidney failure.

The Times gives the example of a 33-year-old Manhattan resident, Lloyd Balch, who was prescribed Levaquin for pneumonia and experienced an array of terrifying symptoms. The article states that in addition to being unable to walk uphill, climb stairs or see clearly, his side effects included dry eyes, mouth and skin, ringing in his ears, delayed urination, heart palpitations, burning pain in his eyes and feet and muscle spasms. Other patients who have taken Levaquin have complained about similar symptoms, the Times reports, adding that adverse reactions to fluoroquinolones such as Levaquin may occur anywhere in the body including the brain, heart, liver, skin, eyes, ears and the gastrointestinal system.

"While it is common for most medications – over the counter or prescription – to have some type of side effect, such serious life threatening reactions are unacceptable," said John Bisnar, founder of Bisnar Chase. "These large pharmaceutical companies put drugs out in the market, which they know can be extremely dangerous for consumers and yet, they make a conscious decision to put profits over the safety and well-being of their customers."

The U.S. Food and Drug Administration (FDA) in July 2008 issued a black box warning for Levaquin cautioning doctors and patients that the antibiotic can increase the risk of tendonitis and tendon rupture. According to a CNN Health report, that warning came two years after consumer advocacy group Public Citizen started pressuring the FDA to put the warning on drugs such as Cipro and Levaquin.

"It is hard for anybody to imagine that these product manufacturers care more about profits than people's lives," Bisnar said. "But we have seen significant evidence in a number of product liability cases, which show that the only thing that might make corporations more considerate about consumers is the fear that they will be hit with a slew of lawsuits or a multi-million dollar judgment."

About BISNAR CHASE

Bisnar Chase is a California-based products liability law firm with an experienced group of Levaquin attorneys that has gained a reputation for producing consistent results. The firm's lawyers have been featured as experts on NBC, CBS, and Fox 11. Their California class action and personal injury lawyers have assisted thousands of victims of accidents and defective products by obtaining nearly two hundred million dollars in verdicts and settlements for them.

For more information, please call 800-561-4887 or visit http://www.bestattorney.com for a free consultation.

Attributions: http://well.blogs.nytimes.com/2012/09/10/popular-antibiotics-may-carry-serious-side-effects/

http://articles.cnn.com/2008-07-08/health/antibiotics.risk_1_tendon-ruptures-medication-guide-fluoroquinolone?_s=PM:HEALTH

http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm161809.htm

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bisnar Chase
Bisnar Chase
(949) 203-3814
Email >
Visit website